XML 37 R27.htm IDEA: XBRL DOCUMENT
v3.25.3

SEGMENT INFORMATION (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Schedule of Reportable Segment Information | The following table includes information about segment revenue, significant segment expenses, and segment measure of profitability:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Total revenues | $ | 776,133 |  |  | $ | 745,740 |  |  | $ | 2,346,688 |  |  | $ | 2,106,602 |
Less: |  |  |  |  |  |  |
Cost of sales | 140,085 |  |  | 188,457 |  |  | 441,733 |  |  | 444,096 |
R&D expenses |  |  |  |  |  |  |
Research and early pipeline | 93,720 |  |  | 104,915 |  |  | 280,158 |  |  | 331,372 |
Later-stage clinical programs | 251,650 |  |  | 10,078 |  |  | 279,074 |  |  | 17,792 |
Marketed products | 64,108 |  |  | 69,908 |  |  | 170,285 |  |  | 224,511 |
SG&A expenses |  |  |  |  |  |  |
S&M expenses | 131,327 |  |  | 108,945 |  |  | 355,958 |  |  | 351,103 |
G&A expenses | 137,088 |  |  | 144,535 |  |  | 350,852 |  |  | 391,315 |
Other segment expense (income), net (1) | (11,101) |  |  | 12,822 |  |  | 73,154 |  |  | 44,497 |
Net income (loss) | $ | (30,744) |  |  | $ | 106,080 |  |  | $ | 395,474 |  |  | $ | 301,916 |
(1)Other segment expense, net during the three months ended September 30, 2025 and 2024 include intangible asset amortization, interest income and expense, other income (expense) and income tax expense.
Schedule of Disaggregation of Total Net Product Revenues by Product | The following table presents Total Revenues and disaggregates Net Product Revenues by product.
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
VOXZOGO | $ | 218,387 |  |  | $ | 189,785 |  |  | $ | 653,532 |  |  | $ | 526,597 |
VIMIZIM | 182,755 |  |  | 178,158 |  |  | 586,525 |  |  | 548,694 |
NAGLAZYME | 122,025 |  |  | 131,906 |  |  | 365,182 |  |  | 369,584 |
PALYNZIQ | 108,778 |  |  | 90,634 |  |  | 307,985 |  |  | 254,634 |
ALDURAZYME | 53,709 |  |  | 71,029 |  |  | 159,123 |  |  | 144,849 |
BRINEURA | 47,953 |  |  | 37,005 |  |  | 137,007 |  |  | 121,361 |
KUVAN | 24,025 |  |  | 28,115 |  |  | 76,195 |  |  | 92,576 |
ROCTAVIAN | 3,180 |  |  | 7,235 |  |  | 22,889 |  |  | 15,516 |
Total net product revenues | 760,812 |  |  | 733,867 |  |  | 2,308,438 |  |  | 2,073,811 |
Royalty and other revenues | 15,321 |  |  | 11,873 |  |  | 38,250 |  |  | 32,791 |
Total revenues | $ | 776,133 |  |  | $ | 745,740 |  |  | $ | 2,346,688 |  |  | $ | 2,106,602 |
Schedule of Disaggregation of Total Net Product Revenues by Geographic Region | The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for the Company's commercial products sold directly by the Company, except for ALDURAZYME, which is distributed, marketed and sold exclusively by Sanofi worldwide.
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
United States | $ | 274,114 |  |  | $ | 235,515 |  |  | $ | 788,361 |  |  | $ | 655,963 |
Europe | 195,184 |  |  | 191,017 |  |  | 667,900 |  |  | 607,755 |
Latin America | 97,618 |  |  | 111,908 |  |  | 284,018 |  |  | 274,920 |
Rest of world | 140,187 |  |  | 124,398 |  |  | 409,036 |  |  | 390,324 |
Total net product revenues marketed by the Company | 707,103 |  |  | 662,838 |  |  | 2,149,315 |  |  | 1,928,962 |
ALDURAZYME net product revenues marketed by Sanofi | 53,709 |  |  | 71,029 |  |  | 159,123 |  |  | 144,849 |
Total net product revenues | $ | 760,812 |  |  | $ | 733,867 |  |  | $ | 2,308,438 |  |  | $ | 2,073,811 |
Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers | The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Customer A | 14 | % |  | 11 | % |  | 15 | % |  | 13 | %
Customer B | 12 |  |  | 10 |  |  | 11 |  |  | 10 |
Customer C | 11 |  |  | 12 |  |  | 12 |  |  | 11 |
Total | 37 | % |  | 33 | % |  | 38 | % |  | 34 | %

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration